Close
Close

Tesaro, Inc. - Recurrent Ovarian Cancer

Partner

Not provided

Rare Disease

Recurrent Ovarian Cancer

Sponsor

Tesaro, Inc.

Access Program Information

This is an expanded access program (EAP) for eligible patients with Recurrent Ovarian Cancer. This program is designed to provide access to niraparib prior to approval by the US Food and Drug Administration (FDA). To be eligible, patients with Recurrent Ovarian Cancer following a partial (PR) or complete response (CR) to their most recent platinum-based chemotherapy and must have experienced a PR or CR after the penultimate (next to last) platinum-based chemotherapy for at least 6 months without disease progression after this chemotherapy.

Contact
Locations

Free Newsletter